Practice

Change page

Established corticosteroid creams should be applied only once daily in patients with atopic eczema

BMJ 2007; 334 doi: 10.1136/bmj.39195.636319.80 (Published 14 June 2007)
Cite this as: BMJ 2007;334:1272

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Hywel C Williams, professor of dermato-epidemiology
  1. Centre of Evidence Based Dermatology, Queen's Medical Centre, University of Nottingham NG7 2UH
  1. hywel.williams{at}nottingham.ac.uk

    The clinical problem

    Atopic eczema affects many adults and up to 20% of children,1 with health costs comparable to diabetes2 and asthma.3 One community survey of 1760 young children in the United Kingdom found that 84% had mild eczema, 14% moderate, and 2% severe eczema.4 Topical corticosteroids are a mainstay of treatment for inflammatory episodes.5 Most long established topical corticosteroids such as betamethasone valerate or hydrocortisone are applied at least twice daily, but three newer preparations (mometasone, fluticasone, and methylprednisolone) have been developed for once daily application. Here, I propose that established preparations need be applied only once daily.

    The evidence for change

    Ten randomised controlled trials compared once daily versus more frequent application of topical corticosteroids within the same potency group (table⇓). The findings are summarised in a UK Health Technology Assessment report and guidance from the National Institute for Health and Clinical Excellence (NICE).6 7 Another short term study has been published more recently.8 One trial compared once versus twice daily moderately potent topical preparations; eight studies evaluated once versus twice daily …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular